The pathobiology of acute coronary syndromes: Clinical implications and central role of the mitochondria

Texas Heart Institute Journal

Volumn 40, Issue 3, 2013, Pages 221-228

  Buja, L Maximilian ^a  

^a TEXAS HEART INSTITUTE   (United States)

Author keywords

Apoptosis; Autophagy; Cardiac pathology; Cardioprotection; Control; Inflammation mediators; Ischemic preconditioning; Mitochondria; Myocardial; Myocardial ischemia physiopathology; Myocardial reperfusion injury; Myocardial reperfusion injury physiopathology; Myocardial stunning physiopathology; Myocardium cytology ultrastructure; Myocytes; Necrosis prevention ; Oncosis; Regeneration physiology; Reperfusion injury; Signal transduction; Stem cell transplantation

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE; ADENOSINE TRIPHOSPHATE; ADIPOCYTOKINE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CASPASE 3; CASPASE INHIBITOR; CYCLOPHILIN D; CYCLOSPORIN; CYCLOSPORIN A; DELCASERTIB; DNA; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROTEIN BCL 2; PROTEIN KINASE B; SANGLIFEHRIN A; UNCOUPLING PROTEIN 2; UNINDEXED DRUG; VOLTAGE DEPENDENT ANION CHANNEL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; APOPTOSIS; AUTOPHAGY; CELL DAMAGE; CELL DEATH; CLINICAL TRIAL (TOPIC); HEART INFARCTION; HEART INFARCTION SIZE; HEART MITOCHONDRION; HEART MUSCLE ISCHEMIA; HEART PRESERVATION; HUMAN; MOLECULAR PATHOLOGY; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; REVIEW; STEM CELL TRANSPLANTATION;

APOPTOSIS; AUTOPHAGY; CARDIOPROTECTION; INFLAMMATION MEDIATORS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MITOCHONDRIA; MYOCARDIAL ISCHEMIA/PHYSIOPATHOLOGY; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL REPERFUSION INJURY/PHYSIOPATHOLOGY; MYOCARDIAL STUNNING/PHYSIOPATHOLOGY; MYOCARDIUM/CYTOLOGY/ULTRASTRUCTURE; MYOCYTES, CARDIAC/PATHOLOGY; NECROSIS/PREVENTION & CONTROL; ONCOSIS; REGENERATION/PHYSIOLOGY; REPERFUSION INJURY; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

ACUTE CORONARY SYNDROME; ANIMALS; CELL DEATH; DISEASE PROGRESSION; HUMANS; MITOCHONDRIA, HEART; MYOCARDIUM; PROGNOSIS;

EID: 84881180001     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Gimbrone MA, Garcia-Cardena G. Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Car-diovasc Pathol 2013;22(1):9-15.
2. Libby P. Inf lammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32(9):2045-2051.
3. Buja LM, Willerson JT. The role of coronary artery lesions in ischemic heart disease: insights from recent clinicopatholog-ic, coronary arteriographic, and experimental studies. Hum Pathol 1987;18(5):451-461.
4. Libby P. Molecular and cellular mechanisms of the throm-botic complications of atherosclerosis. J Lipid Res 2009;50 Suppl:S352-S357.
5. Fishbein MC. The vulnerable and unstable atherosclerotic plaque. Cardiovasc Pathol 2010;19(1): 6-11.
6. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013;34(10):719-728.
7. Reimer K A, Ideker RE. Myocardial ischemia and infarction: anatomic and biochemical substrates for ischemic cell death and ventricular arrhythmias. Hum Pathol 1987;18(5):462-475.
8. Reimer K A, Jennings RB. Myocardial ischemia, hypoxia, and infarction. In: Fozzard HA, Haber E, Jennings RB. The heart and cardiovascular system: scientific foundations. 2nd ed. New York: Raven Press; 1991. p. 1875-1973.
9. Burke AP, Virmani R. Pathophysiology of acute myocardial infarction. Med Clin North Am 2007;91(4):553-572.
10. Thiene G, Basso C. Myocardial infarction: a paradigm of success in modern medicine. Cardiovasc Pathol 2010;19(1):1-5.
11. Basso C, Rizzo S, Thiene G. The metamorphosis of myocar-dial infarction following coronary recanalization. Cardiovasc Pathol 2010;19(1):22-28.
12. Buja LM. Modulation of the myocardial response to ischemia. Lab Invest 1998;78(11):1345-1373.
13. Buja LM. Myocardial ischemia and reperfusion injury. Car-diovasc Pathol 2005;14(4):170-175.
14. Willerson JT, Buja LM. Myocardial reperfusion: biology, benefits, and consequences. Dialog Cardiovasc Med 2006;11(4):267-278. Available from: http://www.dialogues-cvm. com/document/DCVM42.pdf [cited 2013 Mar 20].
15. Buja LM, Vela D. Cardiomyocyte death and renewal in the normal and diseased heart. Cardiovasc Pathol 2008;17(6): 349-374.
16. Buja LM, Weerasinghe P. Unresolved issues in myocardial re-perfusion injury. Cardiovasc Pathol 2010;19(1):29-35.
17. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357(11):1121-1135.
18. Lavie CJ, Gersh BJ. Mechanical and electrical complications of acute myocardial infarction. Mayo Clin Proc 1990;65(5): 709-730.
19. Buja LM. Vascular responses to percutaneous coronary intervention with bare-metal stents and drug-eluting stents: a perspective based on insights from pathological and clinical studies. J Am Coll Cardiol 2011;57(11):1323-1326.
20. Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R. The importance of the endothelium in athero-thrombosis and coronary stenting. Nat Rev Cardiol 2012;9 (8):439-453.
21. Weerasinghe P, Hallock S, Brown RE, Loose DS, Buja LM. A model for cardiomyocyte cell death: insights into mechanisms of oncosis. Exp Mol Pathol 2013;94(1):289-300.
22. Weerasinghe P, Buja LM. Oncosis: an important non-apop-totic mode of cell death. Exp Mol Pathol 2012;93(3):302-308.
23. Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest 2005;115(3):565-571.
24. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and signif icance. Annu Rev Physiol 2010;72:19-44.
25. Gottlieb R A. Cell death pathways in acute ischemia/reperfu-sion injury. J Cardiovasc Pharmacol Ther 2011;16(3-4):233-238.
26. Gottlieb RA, Mentzer RM. Autophagy: an affair of the heart. Heart Fail Rev 2012 Nov 28. Epub ahead of print.
27. Hickson-Bick DL, Jones C, Buja LM. Stimulation of mito-chondrial biogenesis and autophagy by lipopolysaccharide in the neonatal rat cardiomyocyte protects against programmed cell death. J Mol Cell Cardiol 2008;44(2):411-418.
28. Yan L, Sadoshima J, Vatner DE, Vatner SF. Autophagy in ischemic preconditioning and hibernating myocardium. Au-tophagy 2009;5(5):709-712.
29. Webster K A. Programmed death as a therapeutic target to reduce myocardial infarction. Trends Pharmacol Sci 2007;28 (9): 429-492.
30. Webster KA. Mitochondrial death channels. Am Sci 2009;97 (5): 38 4-91.
31. Kung G, Konstantinidis K, Kitsis RN. Programmed necrosis, not apoptosis, in the heart. Circ Res 2011;108(8):1017-1036.
32. Konstantinidis K, Whelan RS, Kitsis RN. Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol 2012; 32 (7):1552- 1562.
33. Whelan RS, Konstantinidis K, Wei AC, Chen Y, Reyna DE, Jha S, et al. Bax regulates primary necrosis through mitochon-drial dynamics. Proc Natl Acad Sci U S A 2012;109(17): 6566-6571.
34. Kristen AV, Ackermann K, Buss S, Lehmann L, Schnabel PA, Haunstetter A, et al. Inhibition of apoptosis by the intrinsic but not the extrinsic apoptotic pathway in myocardial ischemia-reperfusion. Cardiovasc Pathol 2013 Feb 11. Epub ahead of print.
35. Mills EM, Xu D, Fergusson MM, Combs CA, Xu Y, Finkel T. Regulation of cellular oncosis by uncoupling protein 2. J Biol Chem 2002;277(30):27385-27392.
36. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83 (4):1113 -1151.
37. Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. Heart Fail Rev 2007;12(3-4):181-188.
38. Yang X, Cohen M V, Downey JM. Mechanism of cardiopro-tection by early ischemic preconditioning. Cardiovasc Drugs Ther 2010;24(3):225-234.
39. Smith CC, Yellon DM. Adipocytokines, cardiovascular pathophysiology and myocardial protection. Pharmacol Ther 2011;129(2):206-219.
40. Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 2008;103(6):501-513.
41. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359(5):473-481.
42. Morel O, Perret T, Delarche N, Labeque JN, Jouve B, Elbaz M, et al. Pharmacological approaches to reperfusion therapy. Cardiovasc Res 2012;94(2):246-252.
43. Oerlemans MI, Koudstaal S, Chamuleau SA, de Kleijn DP, Doevendans PA, Sluijter J P. Targeting cell death in the reper-fused heart: pharmacological approaches for cardioprotec-tion. Int J Cardiol 2013;165(3):410-422.
44. Bell RM, Yellon DM. Conditioning the whole heart--not just the cardiomyocyte. J Mol Cell Cardiol 2012;53(1):24-32.
45. Hausenloy DJ, Boston-Griff iths E, Yellon DM. Cardioprotec-tion during cardiac surgery. Cardiovasc Res 2012;94(2):253-265.
46. Sharma V, Bell RM, Yellon DM. Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy. Expert Opin Pharmacother 2012; 13(8):1153-1175.
47. Gerczuk PZ, Kloner RA. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol 2012;59(11): 969-978.
48. Whittington HJ, Hall AR, McLaughlin C P, Hausenloy DJ, Yellon DM, Mocanu MM. Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther 2013;27(1):5-16.
49. Rocha M, Hernandez-Mijares A, Garcia-Malpartida K, Banuls C, Bellod L, Victor VM. Mitochondria-targeted anti-oxidant peptides. Curr Pharm Des 2010;16(28):3124-3131.
50. Szeto HH, Schiller PW. Novel therapies targeting inner mi-tochondrial membrane--from discovery to clinical development. Pharm Res 2011;28(11):2669-2679.
51. Bell R, Beeuwkes R, Botker HE, Davidson S, Downey J, Gar-cia-Dorado D, et al. Trials, tribulations and speculation! Report from the 7th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol 2012;107(6):300.
52. Buja LM, Vela D. Current status of the role of stem cells in myocardial biology and repair. Cardiovasc Pathol 2011;20(5): 297-301.
53. Kajstura J, Rota M, Cappetta D, Ogorek B, Arranto C, Bai Y, et al. Cardiomyogenesis in the aging and failing human heart. Circulation 2012;126(15):1869-1881.
54. Karantalis V, Balkan W, Schulman IH, Hatzistergos KE, Hare JM. Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol 2012;303(3):H256-H270.
55. Ptaszek LM, Mansour M, Ruskin JN, Chien KR. Towards regenerative therapy for cardiac disease. Lancet 2012;379 (9819):933-942.
56. Rodriguez-Porcel M, Kronenberg M W, Henry TD, Traverse JH, Pepine CJ, Ellis SG, et al. Cell tracking and the development of cell-based therapies: a view from the Cardiovascular Cell Therapy Research Network. JACC Cardiovasc Imaging 2012;5 (5):559-565.
57. Vela DC, Silva GV, Assad JA, Sousa AL, Coulter S, Fernandes MR, et al. Histopathological study of healing after allogen-ic mesenchymal stem cell delivery in myocardial infarction in dogs. J Histochem Cytochem 2009;57(2):167-176.
58. Gahremanpour A, Vela D, Zheng Y, Silva G V, Fodor W, Cardoso CO, et al. Xenotransplantation of human unrestricted somatic stem cells in a pig model of acute myocardial infarction. Xenotransplantation 2013;20(2):110-122.
59. Buja LM, Vela D. Immunologic and inf lammatory reactions to exogenous stem cells: implications for experimental studies and clinical trials for myocardial repair. J Am Coll Cardiol 2010;56 (21): 1693-1700.
60. Frohlich J, Al-Sarraf A. Cardiovascular risk and atherosclerosis prevention. Cardiovasc Pathol 2013;22(1):16-18.
61. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk prof ile of heart failure. Nat Rev Cardiol 2011 8;(1)30-41.
62. Liu SS, Monti J, Kargbo HM, Athar M W, Parakh K. Frontiers of therapy for patients with heart failure. Am J Med 2013 126: (1);6-12.